Mission
BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases associated with aging, particularly those affecting muscular and visual functions.
Aging science
By understanding the relationship between natural active substances and degeneration processes BIOPHYTIS is able to identify families of substances capable of acting directly on the mechanism of the disease.
Pipeline
BIOPHYTIS has a portfolio of first-in-class drug candidates, at various stages of development, for treating certain indications of sarcopenia and ARMD, for which there is currently no treatment.
News
03 August 2017

The report of the Key Opinion Leader Breakfast of july 28, in NYC with Roger Fielding, PhD (Tufts University) made available

02 August 2017

Biophytis announces the appointment of Dr Manfred Horst  as Business Development Office. Read the Press Release